ZI-T01-NK92

N/A

Report date: 2025/01/26 17:01:34

Base Information

Drug NameZI-T01-NK92

Drug Alias Nameadoptive cell therapy targeting TGF beta RII (Zelluna Immunotherapy)anti-TGFbetaRII CAR T-cell therapy (Zelluna)anti-TGFbetaRII TCR T-cell therapy (Zelluna)ZI-T01-NK92

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionHuman leukocyte antigen modulatorsTransforming growth factor beta receptor 2 modulators

TargetsTransforming growth factor beta receptor 2Human leukocyte antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZelluna Immunotherapy AS

China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A